在确定 2025 年最值得关注的药物时，我们收集了 160 多位科睿唯安分析师的专业意见，同时查询了 11 个涵盖数百种疾病、药物和市场并贯穿整个创新生命周期的数据集。
| 药物 | 公司 | 治疗领域 | 年 |
| Tezepelumab | Amgen, AstraZeneca plc | 重度哮喘 | 2022 |
| Aducanumab | Biogen Inc., Esai Co Ltd. | 神经病学/精神病学, 阿尔茨海默病 | 2021 |
| Relugolix | ASKA?Pharmaceutical Co. Ltd., Gedeon Richter, Myovant Sciences Ltd, Pfizer Inc., Takeda Pharmaceutical Co. Ltd. | 前列腺癌, 生殖健康 - 子宫内膜异位症和子宫肌瘤, 肿瘤 | 2021 |
| Vericiguat? | Bayer AG, Merck & Co. | 心血管——心力衰竭 | 2021 |
| Filgotinib (GLPG-0634) | Galapagos NV, Gilead Sciences Inc. | 过度免疫反应/自身免疫病 | 2020 |
| Inclisiran (ALN-PCSsc; ALN-60212; PCSK9si; Leqvio) | The Medicines Co. | 心血管疾病 | 2020 |
| Lisocabtagene maraleucel (JCAR-017; Liso-cel) | Celgene Corporation | 肿瘤 | 2020 |
| Ofatumumab (OMB-157; Kesimpta) | Novartis International AG | 神经病学/精神病学 | 2020 |
| Ozanimod (RPC-1063; Zeposia) | Celgene Corporation | 神经病学/精神病学 | 2020 |
| Rimegepant (BHV-3000; Nurtec) | Biohaven Pharmaceutical Holding Co. Ltd. | 神经病学/精神病学 | 2020 |
| Sacituzumab govitecan (IMMU-132) | Immunomedics Inc., Medicine Inc. | 肿瘤 | 2020 |
| Semaglutide (Rybelsus) | Novo Nordisk A/S | 内分泌/代谢疾病 | 2020 |
| Trastuzumab deruxtecan (DS-8201a; Enhertu) | AstraZeneca plc, Daiichi Sankyo Co. Ltd. | 肿瘤 | 2020 |
| Vadadustat | Akebia Therapeutics Inc., Mitsubishi Tanabe Pharma America Inc., Otsuka Pharmaceutical | 慢性病的并发症 | 2020 |
| Valoctocogene roxaparvovec (BMN-270; Valrox) | Biomarin Pharmaceutical Inc. | 遗传性疾病 | 2020 |
| Betibeglogene darolentivec (LentiGlobin) | Bluebird Bio Inc. | 遗传性疾病 | 2019 |
| Onasemnogene abeparvovec (AVXS-101; Zolgensma) | AveXis | 遗传性疾病 | 2019 |
| Palforzia (AR101; Aerumab) | Aimmune Therapeutics | 过度免疫反应/自身免疫病 | 2019 |
| Ravulizumab (ALXN-1210; Ultomiris) | Alexion Pharmaceuticals Inc. | 过度免疫反应/自身免疫病, 遗传性疾病 | 2019 |
| Risankizumab (BI-655066; ABBV-066; Skyrizi) | AbbVie Inc., Boehringer Ingelheim | 过度免疫反应/自身免疫病 | 2019 |
| Roxadustat (FG-4592; AZD-9941; ASP-1517; Ai Rui Zhuo) | Astellas Pharma Inc., AstraZeneca plc, FibroGen | 慢性病的并发症 | 2019 |
| Upadacitinib (ABT-494; Rinvoq) | AbbVie Inc. | 过度免疫反应/自身免疫病 | 2019 |
| Apalutamide (Erleada) | Johnson & Johnson | 肿瘤 | 2018 |
| Buprenorphine (Sublocade) | Indivior plc | 成瘾 | 2018 |
| Cannabidiol (Epidiolex) | GW Pharmaceuticals plc | 神经病学/精神病学 | 2018 |
| Elagolix (Orilissa) | AbbVie Inc. | 生殖健康 | 2018 |
| Emicizumab (Hemlibra) | Chugai, Roche | 血液学 | 2018 |
| Erenumab (Aimovig) | Amgen, Novartis International AG | 神经病学/精神病学 | 2018 |
| Ertugliflozin (Steglatro) | Merck & Co., Pfizer Inc. | 内分泌/代谢疾病 | 2018 |
| Lanadelumab (Takhzyro) | Shire | 遗传性疾病 | 2018 |
| Patisiran (Onpattro) | Alnylam Pharmaceuticals Inc., Sanofi Genzyme | 遗传性疾病 | 2018 |
| Shingrix vaccine | GlaxoSmithKline plc | 传染病 | 2018 |
| Tenofovir alafenamide plus emtricitabine plus bictegravir (Biktarvy) | Gilead Sciences Inc. | 传染病 | 2018 |
| Avelumab (Bavencio) | Merck Serono, Pfizer Inc. | 肿瘤 | 2017 |
| Axicabtagene ciloleucel (KTE-C19; Yescarta) | Kite Pharma | 肿瘤 | 2017 |
| Baricitinib (Olumiant) | Eli Lilly and Co., Incyte Corp. | 过度免疫反应/自身免疫病 | 2017 |
| Dupilumab (Dupixent) | Regeneron Pharmaceuticals Inc., Sanofi SA | 过度免疫反应/自身免疫病 | 2017 |
| Durvalumab (Imfinzi) | AstraZeneca plc | 肿瘤 | 2017 |
| Niraparib (Zejula) | Tesaro | 肿瘤 | 2017 |
| Ocrelizumab (Ocrevus) | Roche | 神经病学/精神病学 | 2017 |
| Ribociclib (LEE-011; Kisqali) | Novartis International AG | 肿瘤 | 2017 |
| Semaglutide (Ozempic) | Novo Nordisk A/S | 内分泌/代谢疾病 | 2017 |
| Emtricitabine plus tenofovir alafenamide (Descovy) | Gilead Sciences Inc., Japan Tobacco | 传染病 | 2016 |
| Grazoprevir plus elbasvir (MK-5172A) | Merck & Co. | 传染病 | 2016 |